Tunneled Catheters and Implanted Ports

Indications

Contraindications

• Ipsilateral DVT or SVC syndrome — relative; may require alternative site or SVC recanalization before device placement.
• Active systemic infection or bacteremia — place after source control; tunneled device is not appropriate in the setting of active sepsis.
• Platelet count <50,000 or INR >2.5 for elective placement — correct coagulopathy first.
• Skin infection overlying intended tunnel tract or pocket site — avoid tunneling through infected tissue; select alternative site.
• Prior radiation to chest affecting skin healing — relative contraindication; assess skin integrity and vascularity before proceeding; radiation-damaged skin increases risk of wound dehiscence and port erosion.

Relevant Anatomy

Venous Access

The right internal jugular vein (IJV) is the preferred access site for both tunneled catheters and implanted ports — it provides the most direct, predictable path to the SVC with minimal angulation. The left IJV is acceptable but involves a longer path with more angulation at the left brachiocephalic junction, increasing the risk of catheter kinking. The subclavian vein is an alternative but carries the risk of pinch-off syndrome — chronic compression of the catheter between the clavicle and first rib leads to catheter fatigue, fracture, and potential embolism of the distal fragment. Avoid subclavian access if a contralateral port or tunneled catheter is already in place, as bilateral subclavian devices further crowd the SVC.

Tunnel Tract

The subcutaneous tunnel runs from the venous entry site at the neck to the exit site on the anterior chest wall, typically below the clavicle and lateral to the sternum. The tunnel should follow a smooth, gradual curve — acute angulation at any point along the tract can cause catheter kinking, functional obstruction, and accelerated device wear. For implanted ports, the tunnel terminates at the port pocket rather than an exit site on the skin surface.

Port Pocket

The port reservoir is placed in the anterior chest wall subcutaneous tissue, typically in the infraclavicular region. Pocket size should be matched to the port body diameter — too large a pocket allows port rotation and flipping (port flip); too small a pocket causes wound closure tension and dehiscence risk. Ensure adequate subcutaneous tissue depth for port coverage; bony prominences should be avoided. Patient body habitus and preference for port position should be considered, particularly in post-mastectomy patients who may prefer contralateral chest or lower chest positioning.

Catheter Tip Position

The optimal tip position is the lower SVC at the cavo-atrial junction (CAJ), confirmed by fluoroscopy at the time of placement. Tip in the mid-SVC or higher is associated with higher rates of thrombosis and vessel wall erosion. Tip in the right atrium is acceptable if only minimally intra-atrial, but deep right atrial or right ventricular position must be corrected to avoid arrhythmia.

Pre-Procedure Checklist

Site Planning

• Assess prior access history — prior central venous catheters, thrombosis history, previous port or tunneled catheter placements and their complications
• Mastectomy history — avoid ipsilateral axillary and subclavian access in post-mastectomy patients with known lymphedema or axillary dissection; consider contralateral or femoral access
• Prior chest radiation — evaluate skin integrity over planned tunnel tract and pocket site; radiation-damaged skin impairs wound healing
• SVC patency — obtain upper extremity venous ultrasound or CT venogram if clinical concern for SVC syndrome, bilateral upper extremity swelling, or multiple prior central lines
• Plan tunnel tract and pocket location; confirm patient preference for port position

Labs

• Platelet count ≥50,000 for elective placement
• INR ≤2.5 for elective placement; hold anticoagulation per institutional protocol
• Creatinine if contrast venogram anticipated (e.g., to evaluate venous patency)

Consent

• Arterial puncture with hematoma or pseudoaneurysm
• Pneumothorax (low risk with IJV approach; higher with subclavian)
• Pocket hematoma (most common early complication for ports)
• Wound dehiscence with exposed port hardware
• Infection — CLABSI, pocket infection, tunnel infection
• Catheter malposition requiring repositioning
• Fibrin sheath formation causing dysfunction
• Catheter fracture and embolism (rare; higher risk with subclavian access / pinch-off syndrome)
• Long-term complications of retained device including thrombosis and SVC stenosis

Procedure Overview

The following is a high-level summary. Full step-by-step technique, port pocket creation, power port placement, fibrin sheath stripping, and catheter exchange protocols are available in RadCall Pro.

Tunneled Cuffed Catheter

1. Ultrasound-guided venous access — right IJV cannulated under real-time ultrasound guidance; micropuncture technique preferred to minimize arterial injury risk; confirm venous position (compressibility, color Doppler) before upsizing access
2. Fluoroscopic wire positioning — advance wire under fluoroscopy to the IVC; confirm position to ensure wire has not entered the contralateral brachiocephalic vein or right ventricle
3. Tunnel creation — infiltrate local anesthetic along the planned tunnel tract from exit site to venous access site; tunneling device (Bing tunneler or equivalent) is passed subcutaneously; the catheter is pulled through the tunnel with the Dacron cuff positioned 1–2 cm from the exit site (cuff must be deep to the skin to allow fibrous ingrowth without extrusion)
4. Catheter trimming and insertion — trim catheter to appropriate length to position the tip at the cavo-atrial junction; advance catheter over wire via peel-away introducer sheath; confirm tip position fluoroscopically; for dialysis catheters, select the appropriate sized catheter based on patient body habitus and measured insertion length
5. Closure and dressing — place purse-string or figure-of-eight suture at venotomy site if required; close exit site with simple suture; apply sterile dressing; do not place suture directly over cuff

Implanted Port (Additional Steps)

1. Steps 1–2: Identical venous access and fluoroscopic wire positioning as above
2. Pocket creation — incision in the infraclavicular skin; blunt dissection of a subcutaneous pocket sized to the port body; meticulous hemostasis is critical — pocket hematoma is the most common early complication and increases infection risk
3. Port connection — connect catheter to port reservoir; ensure secure locking connection with no kinking at the junction; secure port body to underlying fascia with non-absorbable suture to prevent port flip
4. Wound closure — layered closure of port pocket with absorbable suture for deep layers; subcuticular skin closure; access port with a non-coring Huber needle to confirm blood return and flush before leaving the procedure room — document confirmed function in report

Complications

Fibrin Sheath Management

All central venous catheters develop fibrin deposits on their outer surface within days of placement; a clinically significant fibrin sheath forms a sleeve around the catheter that can obstruct aspiration (one-way valve effect), infusion, or both. Fibrin sheath is the leading cause of tunneled catheter and port dysfunction and should be suspected when blood return is lost but the device still flushes, or when the patient reports resistance during infusion.

tPA Instillation (First-Line)

• Alteplase (tPA) 2 mg in 2 mL per lumen; instill and allow to dwell for 30–120 minutes
• Aspirate before flushing to remove the clot/fibrin plug; do not forcefully flush without confirmed blood return
• Can repeat up to two doses per session if first instillation is unsuccessful
• For ports, access with Huber needle before instillation

Fibrin Sheath Stripping (Refractory Cases)

• Performed via femoral venous access; a snare catheter is advanced under fluoroscopy from the groin and looped around the existing tunneled catheter
• The snare is advanced retrograde (toward the catheter tip) to strip the fibrin sleeve off the catheter outer surface; effective for long-dwell catheters refractory to repeated tPA
• The existing catheter remains in place; no exchange required if the device is otherwise intact

Catheter Exchange Over Wire

• If fibrin sheath stripping fails to restore function, or if the catheter itself is damaged, perform catheter exchange over wire through the existing tunnel tract
• New catheter placed through existing peel-away sheath over wire; reuse of the tunnel avoids repeat tunneling procedure and preserves the Dacron cuff location
• An angioplasty balloon advanced over the wire can also be used to macerate the fibrin sheath prior to exchange, disrupting the sleeve and improving new catheter seating

CRBSI — Device Removal vs. Salvage

Management of catheter-related bloodstream infection (CRBSI) in tunneled catheters and ports is governed by the IDSA 2009 guidelines and the KDOQI 2019 vascular access guidelines. The decision to remove or salvage the device depends on the causative organism, clinical stability, and site of infection.

Indications for Mandatory Removal (IDSA A-II)

Long-term catheters must be removed in any of the following circumstances:

• Severe sepsis or hemodynamic instability
• Suppurative thrombophlebitis
• Endocarditis
• Bloodstream infection persisting >72 hours despite appropriate antimicrobial therapy
• Infection due to S. aureus, P. aeruginosa, fungi, or mycobacteria
• Tunnel infection or port pocket abscess — remove device + incision and drainage if fluctuant; 7–10 days of antibiotic therapy
• Exit site infection with purulent drainage failing systemic antibiotics (B-II)

Catheter Salvage — When It May Be Attempted (IDSA B-II)

For uncomplicated CRBSI involving long-term catheters, salvage with systemic antibiotics plus antibiotic lock therapy may be attempted when all of the following are true:

• Organism is not S. aureus, P. aeruginosa, Bacillus spp., Micrococcus spp., Propionibacteria, fungi, or mycobacteria
• No tunnel or pocket infection
• No metastatic complications (endocarditis, suppurative thrombophlebitis)
• Patient is clinically stable
• Limited alternative venous access (e.g., hemodialysis patients, short-gut syndrome)

Guidewire Exchange

If no alternative vascular site is available and/or the patient has a significant bleeding diathesis, the infected catheter may be exchanged over a guidewire — provided there is no exit site or tunnel infection (IDSA B-III). An antimicrobial-impregnated catheter with anti-infective intraluminal surface should be used when available (B-II).

Special Consideration: S. aureus CRBSI

• Short-term catheters: remove immediately (A-II)
• Long-term catheters: removal is strongly recommended unless major contraindications exist (no alternative venous access, significant bleeding diathesis, or quality-of-life considerations) (A-II)
• If a long-term catheter is retained in the rare circumstance of S. aureus CRBSI, treat with systemic antibiotics plus antibiotic lock therapy for 4 weeks (B-II)
• In cancer patients: early removal within 3 days is associated with better outcomes^[3]

KDOQI Guidance for Hemodialysis Catheters

KDOQI 2019 specifies that immediate CVC removal with delayed replacement at a new site is warranted for: hemodynamically unstable patients; persistent fever or bacteremia 48–72h after initiating antibiotics; metastatic complications; infections due to S. aureus, P. aeruginosa, fungi, or mycobacteria; and tunnel-site infection. Antibiotic lock therapy plus systemic antibiotics may preserve the CVC in selected patients, though no RCTs have confirmed superiority over removal.

Special Population: Hematologic Malignancies

In patients with hematologic malignancies or stem cell transplant recipients, catheter removal rates in CRBSI may be as low as 25% due to thrombocytopenia and limited access.^[3] However, retaining the catheter without salvage measures carries a 46% infection recurrence rate. For S. aureus bacteremia in cancer patients, early removal within 3 days improves outcomes regardless of thrombocytopenia.^[3]

Summary: Organism-Based Decision Table

Post-Procedure Care

• Tip position confirmation — document fluoroscopic tip position at the cavo-atrial junction in the procedure report; note any need for repositioning
• Dressing and wound care — first dressing change at 24–48 hours; port pocket wound check at 1–2 weeks; patient instruction to protect exit site or port from water until healed
• Patient education — report fever, erythema, swelling, discharge at exit site or over port pocket; tunneled catheter exit site care with chlorhexidine; no submersion until healed
• Flush protocol — tunneled catheter: flush with saline followed by heparin lock (10 units/mL, 3–5 mL per lumen) after each use; Groshong valved catheters use saline flush only (valve prevents backflow)
• Flush protocol — implanted port: saline + heparin lock (100 units/mL, 5 mL) after each access session; monthly heparin flush when port is not in active use to maintain patency
• Huber needle access: use dedicated non-coring Huber needle for all port access — standard beveled needles core the silicone septum and shorten port life; change Huber needle every 7 days if the port is accessed continuously

When to Escalate

• Suspected CRBSI with hemodynamic instability or severe sepsis — remove device promptly regardless of organism; blood cultures x2 (peripheral + through device); broad-spectrum IV antibiotics; ID consultation; see IDSA/KDOQI infection management section for full decision framework
• S. aureus bacteremia with retained device — remove tunneled catheter or port; echocardiogram (TTE then TEE if negative) to exclude endocarditis; minimum 4–6 weeks IV antibiotics for confirmed endocarditis; early removal within 3 days improves outcomes in cancer patients
• Catheter embolism — fluoroscopic localization of embolized fragment; percutaneous snare retrieval in IR suite; cardiology consultation for fragments lodged in the right ventricle or pulmonary outflow tract
• Wound dehiscence with exposed port — device at high risk for infection with hardware exposure; aggressive wound care and plastic surgery consultation; early device removal if signs of infection develop — do not delay removal in the setting of frank wound infection with exposed metal

References

1. Mermel LA, Allon M, Bouza E, et al. Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the IDSA. Clin Infect Dis. 2009;49(1):1–45.
2. Lok CE, Huber TS, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis. 2020;75(4 Suppl 2):S1–S164.
3. Zakhour R, Chaftari AM, Raad II. Catheter-related infections in patients with haematological malignancies: novel preventive and therapeutic strategies. Lancet Infect Dis. 2016;16(11):e241–e250.
4. Teichgraber UK et al. Central venous port systems as an integral part of chemotherapy. Dtsch Arztebl Int. 2011.
5. Schiffer CA et al. Central venous catheter care for the patient with cancer: ASCO clinical practice guideline. J Clin Oncol. 2013;31(10):1357–1370.
6. O'Grady NP et al. Guidelines for the prevention of intravascular catheter-related infections. CDC/HICPAC. 2011.
7. Funaki B. Central venous access: a primer for the diagnostic radiologist. AJR. 2002.